CEO John Valliant, Ph.D., commented, “In the first quarter, we demonstrated the potential of FPI-2265 to serve as an important new treatment option for patients with mCRPC, presenting interim data from the TATCIST trial at the 2024 AACR Annual Meeting that we believe represent compelling early clinical activity and tolerability data. We look forward to continuing to develop FPI-2265 as the most advanced actinium-based prostate specific membrane antigen targeting therapy and expect to begin a Phase 2 dose optimization trial in the second quarter of this year, followed by a Phase 3 global registrational trial in 2025. In parallel, we are progressing our other clinical-stage programs as part of our diverse portfolio of alpha-emitting RCs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FUSN:
- Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
- Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
- Fusion Pharmaceuticals management to meet with Oppenheimer
- Fusion Pharmaceuticals downgraded to Hold from Buy at TD Cowen
- Fusion announces presentation of data from Phase 2 TATCIST clinical trial